Cradle Growth invests SEK 20 million in Suturion to accelerate the company’s commercial expansion
Lund, October 21, 2026
Suturion has entered into an investment agreement with Cradle Growth AB.
Cradle Growth is a newly established Nordic growth equity and venture capital firm focused on investing in healthcare and life science companies in the early commercial stage. The investment amounts to SEK 20 million and is being made through a convertible loan instrument.
The investment represents Cradle Growth’s third investment since it was established.
In parallel with the investment, Suturion is conducting a rights issue for existing shareholders on terms equivalent to those offered to Cradle Growth. This allows both existing and new investors to participate in the company’s continued development and growth.
As part of the investment agreement, Suturion has committed to broadening its investor base and facilitating an additional capital raise of SEK 10–20 million from new investors.
The combined capital injection strengthens Suturion’s financial position and provides the resources needed to accelerate the company’s commercial activities.
Suturion is currently focused on establishing a network of reference hospitals across Europe. Several product evaluations are currently underway at leading hospitals in the European Union and the Middle East. These hospitals are expected to serve as important reference sites supporting future commercial adoption and market expansion. During 2027, the company plans to gradually increase its focus on the U.S. market.
“Suturion represents an investment opportunity with a rare combination of cleared regulatory status in key markets, solid IP protection and convincing health economic data in a product category that has not seen much innovation lately.”
Fredrik Mattsson, CEO of Cradle Growth
“Cradle Growth’s investment is a strong validation of both our technology and our commercial strategy. Together with the continued support from our existing shareholders, this financing provides the resources needed to accelerate our market expansion and establish a strong foundation for continued growth in Europe and future expansion into the United States.”
Paan Hermansson, CEO of Suturion
The investment proceeds will primarily be directed toward strengthening Suturion’s commercial presence at leading European reference hospitals, driving broader market adoption, and advancing preparations for expansion into the U.S. market.
About Suturion
Suturion AB is a Swedish MedTech company founded in 2018 by surgeon Dr. Gabriel Börner and headquartered in Lund, Sweden. The company has developed SutureTOOL™, an innovative device designed to standardize abdominal wall closure following open abdominal surgery. By facilitating the use of the evidence-based small-bites technique, Suturion aims to improve consistency in surgical practice and support better patient outcomes.
About Cradle Growth
Cradle Growth is a growth equity investor focused on healthcare and life science companies in the early commercial phase across the Nordic region. Cradle makes minority investments in companies with established revenues within medical devices, in-vitro diagnostics, life science tools, and tech-enabled care. As an active owner, Cradle contributes industry experience and expertise through hands-on board participation.
For more information, visit www.cradlegrowth.se
